RETA stock extends gains as Citi welcomes regulatory win (NASDAQ:RETA)
seekingalpha.com
finance
2022-05-27 16:20:37

aluxum/E+ via Getty Images Plano, Texas-based Reata Pharmaceuticals (NASDAQ:RETA) is trading higher for the second straight session on Friday as Citi welcomes the company's recent announcement of the FDA's Priority Review granted for its marketing application for omaveloxolone in Friedreich's ataxia (FA). The designation is in line with the firm's expectations for the candidate, Citi said, noting that omaveloxolone, one of Reata's (RETA) lead assets, is a New Chemical Entity (NCE) and FA is a condition with no approved therapies, currently.
